Supplemental Table 1. Baseline characteristics of Fremantle Diabetes Study Phase II participants with type 2 diabetes categorized by angiotensin converting enzyme inhibitor and/or angiotensin receptor blocker use.

|  |  |  |  |
| --- | --- | --- | --- |
|  | No ACEi/ARB use | ACEi/ARB use | *P*-value |
| Number | 500 (33.7) | 982 (66.3) |  |
| Age (years) | 62.6±12.9 | 67.4±10.5 | <0.001 |
| Male (%) | 48.4 | 53.2 | 0.09 |
| Education beyond primary level (%) | 89.4 | 85.2 | 0.033 |
| Not fluent in English (%) | 9.6 | 11.2 | 0.37 |
| Married/*de facto* (%) | 61.4 | 62.8 | 0.61 |
| Ethnic background (%) Anglo-Celt | 49.6 | 55.2 |  |
| S. European | 10.6 | 13.6 |  |
| Other European | 8.0 | 6.4 | 0.005 |
| Asian | 5.4 | 4.0 |
| Aboriginal/TSI | 10.2 | 5.7 |  |
| Mixed/other | 16.2 | 15.1 |  |
| Smoking status (%) Never | 43.4 | 42.0 |  |
| Ex- | 42.8 | 48.9 | 0.010 |
| Current | 13.7 | 9.1 |  |
| Alcohol consumption (standard drinks/day) | 0.1 [0-1.2] | 0.1 [0-1.2] | 0.45 |
| Age at diabetes diagnosis (years) | 54.6±13.0 | 56.0±11.8 | 0.036 |
| Diabetes duration (years) | 5.0 [2.0-13.0] | 10.2 [3.3-16.9] | <0.001 |
| Diabetes treatment (%) Lifestyle/diet | 30.7 | 20.9 |  |
|  OGLMa | 54.7 | 53.2 | <0.001 |
| Insulin alone | 6.0 | 5.3 |
| Insulin+OGLM | 8.6 | 20.7 |  |
| HbA1c (%) | 6.8 [6.2-7.8]  | 6.8 [6.3-7.6] | 0.61 |
| HbA1c (mmol/mol) | 51 [44-62] | 51 [45-60] | 0.61 |
| Fasting serum glucose (mmol/L) | 7.2 [6.1-9.1] | 7.1 [6.1-8.7] | 0.57 |
| ABSIb (m11/6.kg-2/3) | 0.081±0.005 | 0.082±0.005 | 0.001 |
| Body mass index (kg/m2) | 30.5±5.8 | 31.6±6.1 | 0.002 |
| Heart rate (beats/min) | 70±12 | 70±13 | 0.37 |
| Supine systolic blood pressure (mmHg) | 144±22 | 147±22 | 0.017 |
| Supine diastolic blood pressure (mmHg) | 81±12 | 79±12 | 0.003 |
| Antihypertensive medication (%) | 24.4 | 100 | <0.001 |
| Beta blocker (%) | 13.3 | 26.4 | <0.001 |
| Calcium channel blocker (%) | 10.3 | 32.1 | <0.001 |
| Diuretic (%) | 7.3 | 42.0 | <0.001 |
| Total serum cholesterol (mmol/L) | 4.6±1.2 | 4.2±1.1 | <0.001 |
| Serum HDL-cholesterol (mmol/L) | 1.24±0.34 | 1.23±0.34 | 0.84 |
| Serum triglycerides (mmol/L) | 1.5 (0.9-2.6) | 1.5 (0.9-2.6) | 0.84 |
| Lipid-lowering medication (%) | 51.3 | 78.3 | <0.001 |
| Aspirin (%) | 23.5 | 45.1 | <0.001 |
| Urinary albumin:creatinine ratio (mg/mmol) | 2.6 (0.7-9.2) | 3.8 (1.0-15.0) | <0.001 |
| Albuminuria (%) Normal | 67.2 | 53.3 |  |
| Microalbuminuria | 27.9 | 38.1 | <0.001 |
| Macroalbuminuria | 4.9 | 8.7 |  |
| eGFR (mL/min/1.73m2) ≥90 | 46.9 | 33.4 |  |
| 60-89 | 42.7 | 46.3 |  |
| 45-59 | 4.6 | 11.4 | <0.001 |
| 30-44 | 3.8 | 5.9 |  |
| <30 | 2.0 | 3.1 |  |
| Any retinopathy (%) | 32.9 | 39.6 | 0.012 |
| Peripheral sensory neuropathy (%) | 52.0 | 61.9 | <0.001 |
| Prior coronary heart disease (%) | 18.6 | 34.9 | <0.001 |
| Prior cerebrovascular disease (%) | 5.8 | 10.0 | 0.006 |
| Peripheral arterial disease (%) | 16.3 | 25.9 | <0.001 |
| Charlson Comorbidity Index (%) 0 | 79.8 | 72.3 |  |
| 1-2 | 13.4 | 19.3 | 0.005 |
| 3+ | 6.8 | 8.4 |  |
| Prior pneumonia/influenza hospitalization (%) | 3.0 | 2.5 | 0.61 |
| Influenza vaccination within last year (%) | 62.4 (n=465) | 76.6 (n=954) | <0.001 |
| Pneumonia vaccination within last 5 years (%) | 32.6 (n=454) | 47.4 (n=946) | <0.001 |
| FVCc (% predicted) | 87.6 ± 17.8 (n=452) | 85.5 ± 17.7 (n=894) | 0.039 |
| FEV1d (% predicted) | 85.1 ± 18.7 (n=452) | 81.9 ± 18.9 (n=894) | 0.003 |
| FEV1/FVC (%) | 78.5 ± 2.1 (n=452) | 77.8 ± 1.8 (n=894) | <0.001 |
| Allergy/intolerance to ACEi/ARB (%) | 1.4 | 0.8 | 0.29 |

aoral glucose lowering medications and non-insulin injectables, ba body shape index, cforced expiratory volume in one second, dforced vital capacity